214 related articles for article (PubMed ID: 31959947)
41. Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.
Xiong X; Ke X; Wang L; Yao Z; Guo Y; Zhang X; Chen Y; Pang CP; Schally AV; Zhang H
Proc Natl Acad Sci U S A; 2020 Mar; 117(12):6726-6732. PubMed ID: 32156725
[TBL] [Abstract][Full Text] [Related]
42. Growth hormone-releasing hormone receptor mediates cytokine production in ciliary and iris epithelial cells during LPS-induced ocular inflammation.
Ren JL; Yu QX; Ma D; Liang WC; Leung PY; Ng TK; Chu WK; Schally AV; Pang CP; Chan SO
Exp Eye Res; 2019 Apr; 181():277-284. PubMed ID: 30831084
[TBL] [Abstract][Full Text] [Related]
43. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity.
Cai R; Zhang X; Wang H; Cui T; Halmos G; Sha W; He J; Popovics P; Vidaurre I; Zhang C; Mirsaeidi M; Schally AV
Peptides; 2022 Apr; 150():170716. PubMed ID: 34952135
[TBL] [Abstract][Full Text] [Related]
44. Expression of growth hormone-releasing hormone and its receptor splice variants in human prostate cancer.
Halmos G; Schally AV; Czompoly T; Krupa M; Varga JL; Rekasi Z
J Clin Endocrinol Metab; 2002 Oct; 87(10):4707-14. PubMed ID: 12364462
[TBL] [Abstract][Full Text] [Related]
45. Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival.
Florea V; Majid SS; Kanashiro-Takeuchi RM; Cai RZ; Block NL; Schally AV; Hare JM; Rodrigues CO
Proc Natl Acad Sci U S A; 2014 Dec; 111(48):17260-5. PubMed ID: 25404316
[TBL] [Abstract][Full Text] [Related]
46. The growth hormone-releasing hormone receptor: desensitisation following short-term agonist exposure.
Hansen BS; Gerlach LO; Hansen A; Foged C; Andersen PH
Pharmacol Toxicol; 2001 Feb; 88(2):81-8. PubMed ID: 11169166
[TBL] [Abstract][Full Text] [Related]
47. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
48. Effects of an Antagonistic Analog of Growth Hormone-Releasing Hormone on Endometriosis in a Mouse Model and In Vitro.
Köster F; Jin L; Shen Y; Schally AV; Cai RZ; Block NL; Hornung D; Marschner G; Rody A; Engel JB; Finas D
Reprod Sci; 2017 Nov; 24(11):1503-1511. PubMed ID: 28205459
[TBL] [Abstract][Full Text] [Related]
49. Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.
Barabutis N; Schally AV
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20470-5. PubMed ID: 19075233
[TBL] [Abstract][Full Text] [Related]
50. Effects of GHRH Deficiency and GHRH Antagonism on Emotional Disorders in Mice.
Recinella L; Libero ML; Veschi S; Piro A; Marconi GD; Diomede F; Chiavaroli A; Orlando G; Ferrante C; Florio R; Lamolinara A; Cai R; Sha W; Schally AV; Salvatori R; Brunetti L; Leone S
Cells; 2023 Nov; 12(22):. PubMed ID: 37998350
[TBL] [Abstract][Full Text] [Related]
51. Protection of neonatal rat cardiac myocytes against radiation-induced damage with agonists of growth hormone-releasing hormone.
Kiscsatári L; Varga Z; Schally AV; Gáspár R; Nagy CT; Giricz Z; Ferdinandy P; Fábián G; Kahán Z; Görbe A
Pharmacol Res; 2016 Sep; 111():859-866. PubMed ID: 27480202
[TBL] [Abstract][Full Text] [Related]
52. The mutant growth hormone-releasing hormone (GHRH) receptor of the little mouse does not bind GHRH.
Gaylinn BD; Dealmeida VI; Lyons CE; Wu KC; Mayo KE; Thorner MO
Endocrinology; 1999 Nov; 140(11):5066-74. PubMed ID: 10537133
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of experimental small-cell and non-small-cell lung cancers by novel antagonists of growth hormone-releasing hormone.
Wang H; Zhang X; Vidaurre I; Cai R; Sha W; Schally AV
Int J Cancer; 2018 Jun; 142(11):2394-2404. PubMed ID: 29435973
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth.
Zarandi M; Cai R; Kovacs M; Popovics P; Szalontay L; Cui T; Sha W; Jaszberenyi M; Varga J; Zhang X; Block NL; Rick FG; Halmos G; Schally AV
Peptides; 2017 Mar; 89():60-70. PubMed ID: 28130121
[TBL] [Abstract][Full Text] [Related]
55. Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways.
Cui T; Jimenez JJ; Block NL; Badiavas EV; Rodriguez-Menocal L; Vila Granda A; Cai R; Sha W; Zarandi M; Perez R; Schally AV
Oncotarget; 2016 Aug; 7(33):52661-52672. PubMed ID: 27494841
[TBL] [Abstract][Full Text] [Related]
56. Sleep loss alters hypothalamic growth hormone-releasing hormone receptors in rats.
Gardi J; Taishi P; Speth R; Obal F; Krueger JM
Neurosci Lett; 2002 Aug; 329(1):69-72. PubMed ID: 12161265
[TBL] [Abstract][Full Text] [Related]
57. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro.
Csernus V; Schally AV; Groot K
Peptides; 1999; 20(7):843-50. PubMed ID: 10477085
[TBL] [Abstract][Full Text] [Related]
58. GHRH Antagonists Protect Against Hydrogen Peroxide-Induced Breakdown of Brain Microvascular Endothelium Integrity.
Barabutis N; Akhter MS; Uddin MA; Kubra KT; Schally AV
Horm Metab Res; 2020 May; 52(5):336-339. PubMed ID: 32403147
[TBL] [Abstract][Full Text] [Related]
59. Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.
Romero MJ; Lucas R; Dou H; Sridhar S; Czikora I; Mosieri EM; Rick FG; Block NL; Sridhar S; Fulton D; Weintraub NL; Bagi Z; Schally AV
Proc Natl Acad Sci U S A; 2016 Feb; 113(7):1895-900. PubMed ID: 26831066
[TBL] [Abstract][Full Text] [Related]
60. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
